GlaxoSmithKline: Making an impact on emerging markets

Authored by Abbas Hussain, Senior Partner, C-Bridge Capital

Criticaleye recently caught up with Abbas Hussain, President, Emerging Markets at GlaxoSmithKline, to discuss the state of  emerging markets and the initial stages of GSK’s low-cost drug plan, a revolutionary scheme set to change the face of the pharmaceutical industry.

Share this with your Community





Click here to download this insight

DOWNLOAD INSIGHT



Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.


Click here to download this insight

BLOG | Transforming Your Sustainability Strategy

Sustainability remains firmly on the agenda for most organisations, but the way leaders are approaching it is changing. What used to be driven by bold, standalone commitments are now shifting towards a more grounded ...


Mike Maudsley, CEO of enfinium: How Great CEOs Stay Ahead of the Curve

Mike Maudsley, CEO of enfinium, joins Bridgette Hall, Senior Editor at Criticaleye, to explore what it takes to succeed as a CEO in today’s fast-changing business environment. As organisations navigate incr...


Click here to download this insight

Employee Happiness in the Age of AI

In this report, AlixPartners and Darwin X argue that retail consistently trails other industries on employee happiness, and that closing that gap is not just a people issue, but a prerequisite for competing in the ag...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 199




Aldermore Group NatWest Group Stream NATS Southern Water Legal & General Hitachi Solutions Global Payments British Land Canaccord Genuity Group Inc London Stock Exchange Group AlixPartners Drax Group plc Lightsource bp E.ON UK Rolls-Royce LACE Partners GlaxoSmithKline plc CrowdStrike Mayborn Group